Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (3148)	11/7/2020 8:29:02 PM
From: Biotechwantabe	1 Recommendation Recommended By A.J. Mullen Read Replies (1) \| Respond to of 3557

I should have used a sarcastic font. I’m guessing they will come out with pricing after US approval. Base it on value. Shorten hospital stay, save lives... initial Order 300K doses for $450m =1,500. But future orders may have different price. ROW will need to line up with Roche:).

To: A.J. Mullen who wrote (3148)	11/8/2020 4:09:37 PM
From: CuttingEdge Bio	Read Replies (1) \| Respond to of 3557

Peddle your BS elsewhere. REGN's IP did not originate in universities. There is a protection to the taxpayer here. The govt negotiated a price with Regeneron and paid a set price for the drug. Regeneron has done nothing egregious like you imply, and they aren't receiving "egregious profits" for its covid antibodies. But yes, by all means punish them, it will really incentivize companies to innovate and respond quickly to public health emergencies, dumb@ss!